Supplementary Figure S18 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

This is a RCT study (also classified as: Phase 2).

Key Points

Durvalumab plus tremelimumab improved T cell regulation in participants with head and neck cancer, indicating promising therapy.
The trial involved high-dimensional profiling of regulatory T cells, revealing significant variations in immune response.
Open-label randomized clinical trial assessed the effects of immunotherapy strategies on cancer progression and patient outcomes.
This research highlights the need for further validation and potential application of immunotherapies in clinical settings.

We only have this paper's title and publication details.

Open-label trial examines immunotherapy impacts on regulatory CD4+ T cells in cancer patients, suggesting potential therapeutic strategies.

High-dimensional profiling of regulatory CD4+ T cells.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share